Table 2.
Response outcomes
| Outcome | Total (n = 176) | Camrelizumb (n = 103) | Tislelizumab (n = 44) | Sintilimab (n = 20) | Pembrolizumab (n = 9) |
|---|---|---|---|---|---|
| Best response | |||||
| Partial response | 36 (20.5) | 24 (23.3) | 7 (15.9) | 4 (20.0) | 1 (11.1) |
| Stable disease | 103 (58.5) | 59 (57.3) | 26 (59.1) | 12 (60.0) | 6 (66.7) |
| Progressive disease | 37 (21.0) | 20(19.4) | 11 (25.0) | 4 (20.0) | 2 (22.2) |
| Overall response rate | 20.5% | 23.3% | 15.9% | 20.0% | 11.1% |
| Disease control rate | 79.0% | 80.6% | 75.0% | 80.0% | 77.8% |
| Median progression-free survival, day | 234 | 260 | 168 | 260 | 227 |
| Median overall survival, day | 577 | 557 | 518 | 651 | - |
| 1-year overall survival rate | 70.7% | 71.2% | 70.8% | 67.9% | 70.0% |
| 2-year overall survival rate | 41.4% | 41.8% | 42.7% | 38.6% | - |